209 related articles for article (PubMed ID: 37160196)
1. Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction.
Ostrominski JW; Vaduganathan M
Am J Med; 2024 Feb; 137(2S):S9-S24. PubMed ID: 37160196
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
5. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
[TBL] [Abstract][Full Text] [Related]
6. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
7. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
Jhund PS
Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
[TBL] [Abstract][Full Text] [Related]
9. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
Greene SJ; Butler J; Kosiborod MN
Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction.
Clemmer JS; Ward TJ; Lirette ST
ESC Heart Fail; 2023 Jun; 10(3):2010-2018. PubMed ID: 37042079
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
12. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
[TBL] [Abstract][Full Text] [Related]
13. Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin.
Aimo A; Senni M; Barison A; Panichella G; Passino C; Bayes-Genis A; Emdin M
Heart Fail Rev; 2023 Jan; 28(1):179-191. PubMed ID: 35488030
[TBL] [Abstract][Full Text] [Related]
14. The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors.
Chan CG; Stewart R
N Z Med J; 2022 Aug; 135(1560):99-104. PubMed ID: 35999803
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
Banerjee M; Pal R; Nair K; Mukhopadhyay S
Indian Heart J; 2023; 75(2):122-127. PubMed ID: 36914068
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
[TBL] [Abstract][Full Text] [Related]
17. Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?
Schneider CA; Pfister R
Herz; 2022 Oct; 47(5):395-400. PubMed ID: 36018379
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitors in heart failure with preserved ejection fraction.
Faluk M; Wardhere A; Thakker R; Khan FA
Curr Probl Cardiol; 2024 Mar; 49(3):102388. PubMed ID: 38184133
[TBL] [Abstract][Full Text] [Related]
19. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
Pandey AK; Bhatt DL; Pandey A; Marx N; Cosentino F; Pandey A; Verma S
Eur Heart J; 2023 Oct; 44(37):3640-3651. PubMed ID: 37674356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
